Masimo's continuous haemoglobin monitoring tech approved in Japan
This article was originally published in Clinica
Executive Summary
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Masimo's noninvasive, continuous haemoglobin (SpHb) monitoring technology. SpHb is available as part of the firm's Masimo Rainbow SET platform. Haemoglobin monitoring is used in various settings including detecting internal bleeding and anaemia. Irvine, California-based Masimo claims that its device avoids the drawbacks associated with traditional blood testing for haemoglobin, such as the use of needles and the delay when sending the sample to the lab for analysis. The technology received US FDA 510(k) clearance in May 2008 (www.clinica.co.uk, 23 May 2008), and Masimo launched it in "most other countries" in March 2009 (www.clinica.co.uk, 25 March 2009).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.